Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference21 articles.
1. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity;Cornell;Bone Marrow Transplant,2016
2. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?;Sonneveld;Crit Rev Oncol Hematol,2017
3. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update;Nijhof;Drugs,2018
4. Kyprolis: Product Information,2016
5. Kyprolis: Product Information,2016
Cited by 177 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-09
2. Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review;Annals of Hematology;2024-08-27
3. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse;Clinical Lymphoma Myeloma and Leukemia;2024-08
4. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19
5. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review;JAMA Network Open;2024-06-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3